Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Have been diagnosed with lung cancer

• Reside in a rural county as determined by a Rural Urban Continuum Code (RUC) of 4 or higher

• Be at least 18 years of age or older

• Be able to communicate effectively in English

Locations
United States
Kentucky
Markey Cancer Center
RECRUITING
Lexington
Contact Information
Primary
Jerod L Stapleton, PhD
jerod.stapleton@uky.edu
8593237224
Time Frame
Start Date: 2024-08-16
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 300
Treatments
Experimental: Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC)
The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC) is a targeted and tailored lung cancer survivorship care intervention built on principles of patient-centered care, shared decision making, and motivational interviewing to build survivor engagement and improve lung cancer outcomes.
Active_comparator: Enhanced Usual Care (EUC)
The enhanced usual care condition involves usual care plus bibliotherapy and assessment.
Related Therapeutic Areas
Sponsors
Collaborators: University of Louisville, G02 for Lung Cancer, National Cancer Institute (NCI)
Leads: Jerod L Stapleton, PhD

This content was sourced from clinicaltrials.gov